Mrs. Yang Li | Biology and Life Sciences | Best Researcher Award
The First Affiliated Hospital of Kunming Medical University | China
Mrs. Yang Li is a committed attending doctor at the First Affiliated Hospital of Kunming Medical University, where she integrates clinical service with translational research. With a strong foundation in endocrinology and metabolic diseases, her academic and clinical endeavors focus on diabetic complications, particularly type 2 diabetic nephropathy. Her contributions to both provincial and national-level projects highlight her dedication to improving patient outcomes through evidence-based research.
Professional Profile
Scopus
Education
Mrs. Yang Li began her academic journey in clinical medicine at Tongji Medical College, one of China’s top-tier medical institutions. She specialized in endocrinology and metabolic diseases, laying a strong academic foundation in chronic disease management, hormonal regulation, and metabolic dysfunctions. Her education was marked by excellence in both theoretical understanding and hands-on training in hospital environments. Continuing her commitment to academic advancement, she is currently pursuing an academic master’s degree, with research embedded into her clinical role. Her educational path reflects a lifelong commitment to improving the diagnosis, treatment, and understanding of chronic metabolic disorders such as diabetes and its complications.
Experience
Mrs. Li’s professional experience encompasses extensive clinical practice, medical education, and rigorous scientific research. At the First Affiliated Hospital of Kunming Medical University, she functions both as a frontline clinician and a research investigator. Her clinical work has given her firsthand insight into the complexities of diabetic complications, particularly diabetic nephropathy. This experience fuels her research endeavors, allowing her to design studies that are both clinically relevant and methodologically sound. She has independently led two provincially funded research projects and participated in two nationally funded projects under the National Natural Science Foundation of China. Her dual role has equipped her with the skills to integrate clinical questions into laboratory settings and translate scientific findings back into patient care protocols.
Research Interest
Mrs. Li’s core research interests revolve around type 2 diabetic nephropathy, particularly the molecular mechanisms driving renal damage in diabetic patients. Her work investigates the interplay between metabolic stress, adipose tissue function, vascular endothelial integrity, and renal cellular injury. Of special interest is the role of perirenal adipose tissue in modulating the onset and progression of diabetic kidney disease, a relatively underexplored area that may yield novel diagnostic and therapeutic strategies. She is also interested in transcriptomics, signaling pathways such as TGF-β1, and the protective role of ACE2–Ang-(1-7)–Mas receptor axes in pancreatic and renal tissues. Through her research, she aims to uncover early biomarkers and develop targeted interventions that can prevent or slow the progression of diabetic nephropathy.
Award
Mrs. Yang Li is an exemplary nominee for the Best Researcher Award, a recognition that would honor her persistent and impactful contributions to clinical science. Her ability to lead government-funded projects, publish in respected international journals, and remain active in frontline patient care places her among the most promising early-career physician-researchers in China. The translational nature of her research directly addresses one of the world’s most pressing public health concerns: diabetes and its complications. Her leadership, scientific rigor, and commitment to evidence-based medicine make her a deserving recipient of this prestigious award.
Publications
Mrs. Yang Li has published four peer-reviewed articles in reputable SCI-indexed journals, reflecting her growing influence in the field of diabetic complications. Each of her publications contributes to a deeper understanding of the pathophysiological mechanisms behind diabetes and its impact on vital organs:
Title: Ang (1-7) protects islet endothelial cells from palmitate-induced apoptosis via AKT, eNOS, p38 MAPK, and JNK pathways
Journal: Journal of Diabetes Research
Published on: 2014
Citation: Cited by 64 articles
Title: The ACE2–Ang-(1-7)–Mas axis improves microvascular endothelial cell function in pancreatic β cells
Journal: International Journal of Molecular Medicine
Published on: 2014
Citation: Cited by 91 studies
Title: Scutellarin ameliorates diabetic nephropathy via the TGF-β1 signaling pathway
Journal: Natural Products and Bioprospecting
Published on: 2024
Citation: Cited by 6 articles
Title: Transcriptomic analysis of ceRNA regulatory networks in perirenal adipose tissue of T2DM SD rats with diabetic nephropathy
Journal: Biotechnology and Applied Biochemistry
Published on: 2025
Citation: Cited by 2 articles
Conclusion
Mrs. Yang Li exemplifies the integration of clinical excellence and scientific innovation. Her work has advanced the understanding of diabetic nephropathy at both cellular and systemic levels, contributing new insights into its prevention and treatment. By combining patient care with a robust research portfolio, she continues to bridge the gap between laboratory discovery and clinical application. Her academic background, research leadership, and impactful publications collectively highlight her qualifications for prestigious research recognition. With her contributions resonating across endocrinology and nephrology, Mrs. Yang Li stands as a valuable asset to the medical and scientific community.
